

Hemoglobinuria paroxística nocturna

Image



Hemoglobinuria paroxística nocturna

Novedades

[Ver más](#)



Para muchos pacientes con HPN

**LOS SÍNTOMAS
CONTINÚAN¹⁻⁵**

Article

4 mins

Abordaje terapéutico y carga de la enfermedad

Article - 16 Ene 2025


4 mins

Abordaje terapéutico y carga de la enfermedad

[Facebook](#) [X](#) [Linkedin](#)

[See more details](#)

Hide details




Todo sobre HPN

Todo sobre HPN

Ver más

See more details

Hide details



Recursos para profesional sanitario

Recursos para profesional sanitario

Ver más

See more details

Hide details



PROXIMAMENTE

Recursos para pacientes

Recursos para pacientes

Ver más

See more details

Hide details

The logo for 'EspacioCiencia' is centered on a blue background. The word 'Espacio' is in a bold, white, sans-serif font, while 'Ciencia' is in a lighter, white, sans-serif font. A white circle with a drop-like shape inside is positioned between the two words. The background features a network of white lines and dots on the left and a partial view of a green and blue planet on the right.

Espacio  Ciencia

Espacio Ciencia

Espacio Ciencia

Ver más

See more details

Hide details

Image



Solicitud de información médica

¿ Tienes una pregunta específica sobre alguno de nuestros productos o patologías ?

[Contacta con nuestro equipo de Información Médica](#)

Referencias

1. Schrezenmeier H, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. *Ann Hematol.* 2020 Jul;99(7):1505-1514.
2. Fishman J, et al. Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network. *Hematol Rep.* 2023 Apr 21;15(2):266-282.
3. Dingli D, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. *Ann Hematol.* 2022 Feb;101(2):251-263.
4. Schrezenmeier H, et al. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. *Ther Adv Hematol.* 2020 Oct 24;11:2040620720966137.
5. Bektas M, et al. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of

disease. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S8-S14.

Source URL:

<https://www.pro.novartis.com/es-es/hematopro/patologias/hemoglobinuria-paroxistica-nocturna>